PATHanalyst commentary
UiPath shares fell nearly 3% after Cleveland Research highlighted downside risks for annual recurring revenue, citing potential challenges from competition and AI budgets through fiscal 2028.
Seeking Alpha
1 story shown
UiPath shares fell nearly 3% after Cleveland Research highlighted downside risks for annual recurring revenue, citing potential challenges from competition and AI budgets through fiscal 2028.